Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01349972
First received: May 6, 2011
Last updated: October 10, 2014
Last verified: January 2014